Founded Year

2017

Stage

Acquired | Acquired

Total Raised

$4.67M

About Cambridge Cancer Genomics

Cambridge Cancer Genomics uses artificial neural networks and machine learning algorithms to design personalized tests for tracking treatment responses in cancer patients. It follows the progress of a treatment course through a blood sample by applying its proprietary analysis to a tumor's genomic features. The company was founded in 2017 and is based in Cambridge, United Kingdom. In June 2021, Cambridge Cancer Genomics was acquired by Dante Labs.

Headquarters Location

72 Hills Road

Cambridge, England, CB2 1LA,

United Kingdom

Loading...

Loading...

Expert Collections containing Cambridge Cancer Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cambridge Cancer Genomics is included in 3 Expert Collections, including Artificial Intelligence (AI).

A

Artificial Intelligence (AI)

16,578 items

Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.

D

Digital Health

12,122 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

O

Oncology Tech

571 items

This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.

Cambridge Cancer Genomics Patents

Cambridge Cancer Genomics has filed 1 patent.

The 3 most popular patent topics include:

  • artificial neural networks
  • genetics
  • machine learning
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/24/2020

Artificial neural networks, Machine learning, Molecular biology, Genetics, Rare diseases

Application

Application Date

1/24/2020

Grant Date

Title

Related Topics

Artificial neural networks, Machine learning, Molecular biology, Genetics, Rare diseases

Status

Application

Latest Cambridge Cancer Genomics News

Artificial Intelligence In Genomics Market Research Report by Offering, Technology, Functionality, Application, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Jul 8, 2022

by Offering, Technology, Functionality, Application, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06286831/?utm_source=GNW The Global Artificial Intelligence In Genomics Market size was estimated at USD 321.23 million in 2021 and expected to reach USD 423.95 million in 2022, and is projected to grow at a CAGR 32.23% to reach USD 1,717.49 million by 2027. Market Statistics: The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period. Market Segmentation & Coverage: This research report categorizes the Artificial Intelligence In Genomics to forecast the revenues and analyze the trends in each of the following sub-markets: Based on Offering, the market was studied across Services and Software. Based on Technology, the market was studied across Computer Vision and Machine Learning. Based on Functionality, the market was studied across Clinical Workflows, Gene Editing, Genome Sequencing, and Predictive Genetic Testing & Preventive Medicine. Based on Application, the market was studied across Agriculture & animal Research, Diagnostics, Drug Discovery & Development, Other, and Precision Medicine. Based on End User, the market was studied across Government Organizations, Healthcare Providers, Others, Pharmaceutical & Biotech Companies, and Research Centers, Academic Institutes, &. Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market. Cumulative Impact of 2022 Russia Ukraine Conflict: We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Artificial Intelligence In Genomics market considering the current update on the conflict and its global response. Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period. FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Artificial Intelligence In Genomics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape. Market Share Analysis: The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits. Competitive Scenario: The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service. Company Usability Profiles: The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Artificial Intelligence In Genomics Market, including BenevolentAI Ltd., Cambridge Cancer Genomics, Data4Cure Inc., Deep Genomics Inc., DNAnexus Inc., Eli Lilly and Company, Engine Biosciences Pte. Ltd., Fabric Genomics Inc., FDNA Inc., Freenome Holdings, Inc., Genoox Ltd., International Business Machines Corporation, Invitae Corporation, Lifebit Biotech, Microsoft Corporation, MolecularMatch, Inc., NVIDIA Corporation, PrecisionLife Ltd., SOPHiA GENETICS, and Verge Genomics. The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on the market offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments The report answers questions such as: 1. What is the market size and forecast of the Global Artificial Intelligence In Genomics Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Artificial Intelligence In Genomics Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Artificial Intelligence In Genomics Market? 4. What is the competitive strategic window for opportunities in the Global Artificial Intelligence In Genomics Market? 5. What are the technology trends and regulatory frameworks in the Global Artificial Intelligence In Genomics Market? 6. What is the market share of the leading vendors in the Global Artificial Intelligence In Genomics Market? 7. What modes and strategic moves are considered suitable for entering the Global Artificial Intelligence In Genomics Market?

Cambridge Cancer Genomics Frequently Asked Questions (FAQ)

  • When was Cambridge Cancer Genomics founded?

    Cambridge Cancer Genomics was founded in 2017.

  • Where is Cambridge Cancer Genomics's headquarters?

    Cambridge Cancer Genomics's headquarters is located at 72 Hills Road, Cambridge.

  • What is Cambridge Cancer Genomics's latest funding round?

    Cambridge Cancer Genomics's latest funding round is Acquired.

  • How much did Cambridge Cancer Genomics raise?

    Cambridge Cancer Genomics raised a total of $4.67M.

  • Who are the investors of Cambridge Cancer Genomics?

    Investors of Cambridge Cancer Genomics include Dante Labs, Merck Accelerator, Y Combinator, Refactor Capital, Romulus Capital and 6 more.

  • Who are Cambridge Cancer Genomics's competitors?

    Competitors of Cambridge Cancer Genomics include OncoGenomX.

Loading...

Compare Cambridge Cancer Genomics to Competitors

O
OncoGenomX

OncoGenomX's solution, Smart Cancer Diagnostics (SCD), is powered by four innovative technologies: a gene assay to determine the biologic properties of a cancer; an AI software to match effective cancer drugs to a particular cancer; MammaLogX, a continuously learning base of clinical intelligence; and a machine learning software to generate clinical intelligence.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.